Physician-Scientist, Inventor, Author, TEDx Speaker, and Serial Entrepreneur
Joined April 2009
- Tweets 256
- Following 111
- Followers 2,098
- Likes 16
14 Photos and videos
Steven Quay, MD, PhD retweeted
27 Apr 2023
Atossa Therapeutics to Participate in Tribe Public’s Webinar Event “Redefining Breast Cancer Prevention and Treatment” dlvr.it/Sn99Cg
2
6
20
3,320
Steven Quay, MD, PhD retweeted
22 Mar 2023
Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update dlvr.it/SlKMXw
7
23
3,200
Steven Quay, MD, PhD retweeted
21 Mar 2023
Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial dlvr.it/SlGLbz
2
8
37
2,670
Steven Quay, MD, PhD retweeted
15 Mar 2023
Atossa to Present at the Sidoti Small-Cap Virtual Conference dlvr.it/Sky54D
3
20
1,465
Steven Quay, MD, PhD retweeted
23 Feb 2023
Atossa Doses First Patient in Phase 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER /HER2- Breast Cancer dlvr.it/SjtWjj
3
18
53
3,766
Steven Quay, MD, PhD retweeted
13 Feb 2023
Atossa Therapeutics Further Strengthens Intellectual Property Portfolio with Additional Broad Patent for Endoxifen dlvr.it/SjLzvT
2
8
29
1,907
Steven Quay, MD, PhD retweeted
25 Jan 2023
Atossa Therapeutics Issues Letter to Shareholders dlvr.it/ShQpQT
4
10
23
2,130
Steven Quay, MD, PhD retweeted
7 Dec 2022
Atossa Therapeutics Announces the Appointment of Eric Van Zanten as Vice President, Investor and Public Relations dlvr.it/Sf0XTW
17
7
26
Steven Quay, MD, PhD retweeted
8 Nov 2022
Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update dlvr.it/ScPZtT
7
4
13
Steven Quay, MD, PhD retweeted
1 Nov 2022
Atossa Therapeutics, Inc. to Acquire Stake in Privately Held Dynamic Cell Therapies as Part of Overall CAR-T Strategy dlvr.it/Sc3Nmw
1
6
21
Steven Quay, MD, PhD retweeted
25 Oct 2022
Atossa Therapeutics, Inc. Announces Appointment of Pharma Industry Veteran Richard Graydon, M.D., Ph.D. dlvr.it/Sbh6gg
2
7
21
Steven Quay, MD, PhD retweeted
25 Oct 2022
Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate its Phase 2 Study of Neoadjuvant (Z)-endoxifen in Premenopausal Women with ER /HER2- Breast Cancer dlvr.it/SbfXHh
2
10
32
Steven Quay, MD, PhD retweeted
25 Oct 2022
Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Investment Conference dlvr.it/SbfXHd
3
12
Steven Quay, MD, PhD retweeted
25 Oct 2022
Registration Now Open for Tribe Public’s Webinar Event “The Important Role For Inhalation Therapy In Oncology” Featuring The Management Team From Atossa Therapeutics on August 25, 2022 dlvr.it/SbfXHb
2
12
Steven Quay, MD, PhD retweeted
25 Oct 2022
Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board dlvr.it/SbfXHS
4
10
Steven Quay, MD, PhD retweeted
25 Oct 2022
Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update dlvr.it/SbfXGx
6
11
Steven Quay, MD, PhD retweeted
24 Oct 2022
Atossa Therapeutics, Inc. Receives Authorization from FDA to Initiate its Phase 2 Study of Neoadjuvant (Z)-endoxifen in Premenopausal Women with ER /HER2- Breast Cancer dlvr.it/Sbd0Bn
2
9
38
Steven Quay, MD, PhD retweeted
7 Sep 2022
Atossa Therapeutics, Inc. to Attend the 24th Annual H.C. Wainwright Global Investment Conference dlvr.it/SXwC6b
21
3
11
Steven Quay, MD, PhD retweeted
22 Aug 2022
Registration Now Open for Tribe Public’s Webinar Event “The Important Role For Inhalation Therapy In Oncology” Featuring The Management Team From Atossa Therapeutics on August 25, 2022 dlvr.it/SX2st8
4
6
14
Steven Quay, MD, PhD retweeted
18 Aug 2022
Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board dlvr.it/SWrVng
1
7
16